These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1150 related articles for article (PubMed ID: 15824857)
1. TRAF2 is essential for TNF-alpha-induced osteoclastogenesis. Kanazawa K; Kudo A J Bone Miner Res; 2005 May; 20(5):840-7. PubMed ID: 15824857 [TBL] [Abstract][Full Text] [Related]
2. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically. Valverde P; Tu Q; Chen J J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638 [TBL] [Abstract][Full Text] [Related]
3. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation. Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351 [TBL] [Abstract][Full Text] [Related]
4. Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kappaB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha. Kim HJ; Chang EJ; Kim HM; Lee SB; Kim HD; Su Kim G; Kim HH Free Radic Biol Med; 2006 May; 40(9):1483-93. PubMed ID: 16632109 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1. Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185 [TBL] [Abstract][Full Text] [Related]
6. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors. Itoh K; Udagawa N; Matsuzaki K; Takami M; Amano H; Shinki T; Ueno Y; Takahashi N; Suda T J Bone Miner Res; 2000 Sep; 15(9):1766-75. PubMed ID: 10976996 [TBL] [Abstract][Full Text] [Related]
7. Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: a possible mechanism for downregulation of osteoclastogenesis. Kamel Mohamed SG; Sugiyama E; Shinoda K; Hounoki H; Taki H; Maruyama M; Miyahara T; Kobayashi M Biochem Biophys Res Commun; 2005 Apr; 329(3):839-45. PubMed ID: 15752732 [TBL] [Abstract][Full Text] [Related]
8. NMDA glutamate receptors are expressed by osteoclast precursors and involved in the regulation of osteoclastogenesis. Merle B; Itzstein C; Delmas PD; Chenu C J Cell Biochem; 2003 Oct; 90(2):424-36. PubMed ID: 14505357 [TBL] [Abstract][Full Text] [Related]
9. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal. Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731 [TBL] [Abstract][Full Text] [Related]
10. The hematopoietic transcription factor PU.1 regulates RANK gene expression in myeloid progenitors. Kwon OH; Lee CK; Lee YI; Paik SG; Lee HJ Biochem Biophys Res Commun; 2005 Sep; 335(2):437-46. PubMed ID: 16083856 [TBL] [Abstract][Full Text] [Related]
11. JNK/c-Jun signaling mediates an anti-apoptotic effect of RANKL in osteoclasts. Ikeda F; Matsubara T; Tsurukai T; Hata K; Nishimura R; Yoneda T J Bone Miner Res; 2008 Jun; 23(6):907-14. PubMed ID: 18251700 [TBL] [Abstract][Full Text] [Related]
12. Receptor activator of NF-kappaB ligand-stimulated osteoclastogenesis in mouse marrow culture is suppressed by zinc in vitro. Yamaguchi M; Uchiyama S Int J Mol Med; 2004 Jul; 14(1):81-5. PubMed ID: 15202020 [TBL] [Abstract][Full Text] [Related]
13. TRAF5 functions in both RANKL- and TNFalpha-induced osteoclastogenesis. Kanazawa K; Azuma Y; Nakano H; Kudo A J Bone Miner Res; 2003 Mar; 18(3):443-50. PubMed ID: 12619928 [TBL] [Abstract][Full Text] [Related]
15. Tumor necrosis factor-alpha induces differentiation of human peripheral blood mononuclear cells into osteoclasts through the induction of p21(WAF1/Cip1). Kwak HB; Jin HM; Ha H; Kang MJ; Lee SB; Kim HH; Lee ZH Biochem Biophys Res Commun; 2005 May; 330(4):1080-6. PubMed ID: 15823554 [TBL] [Abstract][Full Text] [Related]
16. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways. Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972 [TBL] [Abstract][Full Text] [Related]
17. RANKL-stimulated osteoclast-like cell formation in vitro is partially dependent on endogenous interleukin-1 production. Lee SK; Gardner AE; Kalinowski JF; Jastrzebski SL; Lorenzo JA Bone; 2006 May; 38(5):678-85. PubMed ID: 16309985 [TBL] [Abstract][Full Text] [Related]
18. Differential contribution of osteoclast- and osteoblast-lineage cells to CpG-oligodeoxynucleotide (CpG-ODN) modulation of osteoclastogenesis. Amcheslavsky A; Hemmi H; Akira S; Bar-Shavit Z J Bone Miner Res; 2005 Sep; 20(9):1692-9. PubMed ID: 16059640 [TBL] [Abstract][Full Text] [Related]
19. T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Takayanagi H; Ogasawara K; Hida S; Chiba T; Murata S; Sato K; Takaoka A; Yokochi T; Oda H; Tanaka K; Nakamura K; Taniguchi T Nature; 2000 Nov; 408(6812):600-5. PubMed ID: 11117749 [TBL] [Abstract][Full Text] [Related]
20. RANK signaling is not required for TNFalpha-mediated increase in CD11(hi) osteoclast precursors but is essential for mature osteoclast formation in TNFalpha-mediated inflammatory arthritis. Li P; Schwarz EM; O'Keefe RJ; Ma L; Boyce BF; Xing L J Bone Miner Res; 2004 Feb; 19(2):207-13. PubMed ID: 14969390 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]